Health Discovery Corporation (OTCBB: HDVY) announced today that Stephen D. Barnhill, M.D. has resigned as CEO of the Company to accept a new opportunity. Dr. Barnhill, at the request of the Board of Directors, has agreed to continue as a Consultant and Interim CEO until a suitable replacement CEO is hired and fully educated on the technology and product pipeline thereby ensuring a smooth executive transition.
“The Board of Directors wishes to thank Dr. Barnhill for his numerous contributions to the company and the integral role he has played in the company's growth and successes from founding the Company through leading the Company to a profitable 3 rd Quarter of 2012,” states Dr. Joe McKenzie, Lead Director, “We wish him all the best and look forward to his continued leadership as we search for an experienced senior executive to continue to drive HDC’s growth strategy.”
“Dr. Barnhill is a scientific visionary having brought together the fields of medicine and mathematics in a way that has and will continue to benefit patients worldwide. He is considered an international expert in this new area of medicine and it is a great pleasure to work with him on cutting edge scientific discovery,” states Dr. Herbert Fritsche, Chief Science Officer at HDC and retired Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center, “As an inventor of approximately 36 of the patents owned by HDC, Dr. Barnhill’s contribution to the science driving our technology is remarkable and unprecedented.”
“Starting a public biotech company from its inception and taking it to profitability is no easy task and I could not have achieved this goal without the incredible scientific staff, including Dr. Herb Fritsche and mathematics staff including Dr’s Hong Zhang and Isabelle Guyon, at HDC that have joined together and dedicated themselves to the goal of helping patients through scientific discovery,” states Stephen D. Barnhill, MD, Chairman and CEO of HDC. “The Company is now on a solid path with cash, no long-term debt, products on the market and a pipeline in development, a valuable patent portfolio, and an incredible team in place to continue this success. I look forward to working with the Company to find a new CEO and spending time educating that person on the technology and product pipeline to ensure a smooth transition of executive management.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts